SEC Form 4 · accession 0001237899-17-000019
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert E Landry
Officer — SVP Finance & CFO
Period of report
Aug 7, 2017
Accepted (ET)
Aug 9, 2017 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2017 | M | 2,000 | $272.70 | A | 9,099 | D | |
| Common Stock | Aug 7, 2017 | F | 1,167 | $466.98 | D | 7,932 | D | |
| Common Stock | Aug 7, 2017 | F | 307 | $466.98 | D | 7,625 | D | |
| Common Stock | Aug 8, 2017 | S | 100 | $469.91 | D | 7,525 | D | |
| Common Stock | Aug 8, 2017 | S | 100 | $471.00 | D | 7,425 | D | |
| Common Stock | Aug 8, 2017 | S | 100 | $472.54 | D | 7,325 | D | |
| Common StockF2 | Aug 8, 2017 | S | 226 | $473.57 | D | 7,099 | D | |
| Common Stock | holding | — | — | — | 83 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3 | $272.70 | Aug 7, 2017 | M | 2,000 | D | — | Sep 9, 2023 | Common Stock | 2,000 | 64,000 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2Represents volume-weighted average price of sales of 226 shares of Company stock on August 8, 2017 at prices ranging from $473.27 to $472.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2017 at each separate price.
- F3The stock option award vests in four equal annual installments, commencing one year after the date of grant.